Randomized Clinical Trial to Evaluate the Efficacy of Tamsulosin, Solifenacin, and Their Combination for the Treatment of Stent Related Symptoms
Abstract
Ureteral stents play a major role in a wide range of situations where urinary drainage is needed, the double-J stent which is the most common form of ureteral stent, has been used in obstructive pyelonephritis, intolerable acute renal colic, ureteral edema, ureter perforation following endoscopic procedures, and renal failure secondary to ureteral obstruction. Despite the usefulness of stents, some of the patients might encounter stent-related complications such as urinary tract infection (UTI), lower urinary tract symptoms (LUTS), stent-related body pain, and hematuria. These symptoms represent a prevalent problem with considerable effects on the quality of life, substantial general health, work performance, and sexual performance in both genders. For this reason, several attempts to minimize stentrelated symptoms have recently been reported. Pharmacologic management is one of these trials, especially the prescription of selective alpha-1-blockers as tamsulosin and antimuscarinic agents as solifenacin.
To analyze and assess the effectiveness of a selective alpha-1-blocker (tamsulosin) and antimuscarinic (solifenacin) and their combination in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.
The present study was a prospective randomized controlled comparative study conducted on 112 patients with double-J stent inserted in Ain Shams University Hospital and El-Agouza hospital. over a period of 6 months. The patients were…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 112 participants or records.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.